Primary Surgical Therapy for Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy

Kademani, Deepak; Koka, Sreenivas; Lacy, Martha Q.; Rajkumar, S. Vincent
August 2006
Mayo Clinic Proceedings;Aug2006, Vol. 81 Issue 8, p1100
Academic Journal
Bisphosphonate chemotherapy is commonly used In the treatment of bone diseases such as osteoporosis, Paget disease, and multiple myeloma and to limit bone pain and hypercalcemia associated with malignant metastatic bone lesions. The introduction of bisphosphonate therapy has Improved the quality of life In a vast majority of patients, showing clear medical efficacy. However, since 2003 a growing number of reports have described necrotic bone lesions (osteonecrosis of the jaw [ONJ]) affecting maxillofacial bones in patients who have received chemotherapy with intravenous bisphosphonate therapy. Unfortunately, the development of ONJ has been refractory to conventional treatment modalities. Several treatment options have been proposed for ONJ, most of which focus primarily on conservative management with local irrigation and empirical long-term antibiotic therapy. However, results of treatment have been associated with high failure rates, progression of disease, and continued decline in patients' quality of life. We describe 2 patients in whom primary surgical salvage was performed successfully for ONJ. Our experience indicates that with appropriate technique, primary surgical treatment may offer benefit to selected patients with ONJ.


Related Articles

  • Zoledronic Acid. Cheer, S.M.; Noble, S. // Drugs;Apr2001, Vol. 61 Issue 6, p799 

    â–´ Zoledronic acid (zoledronate) is a new generation bisphosphonate that inhibits osteoclast bone resorption. It was much more potent than other bisphosphonates at inhibiting 1,25-dihydroxyvitamin D-induced hypercalcaemia in a rat model and calcium release in vitro. â–´ A single...

  • Pamidronic acid/zoledronic acid.  // Reactions Weekly;11/27/2010, Issue 1329, p28 

    The article describes the cases of three cancer patients who developed jaw osteonecrosis during chemotherapy with pamidronic acid and/or zoledronic acid.

  • Zoledronic Acid: A Viewpoint by Allan Lipton. Lipton, A. // Drugs;Apr2001, Vol. 61 Issue 6, p806 

    Presents information on zoledronic acid, a bisphosphonate treatment for patients with hypercalcaemia of malignancy. Comparison between zoledronic acid and pamidronic acid, another type of bisphosphonate; Efficacy of the drug.

  • Newly available bisphosphonates improve treatment of hypercalcemia of malignancy. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;03/25/98, Vol. 11 Issue 3, p26 

    Highlights the effectiveness of biphosphonates in improving and simplifying the treatment of malignant hypercalcemia. Affinity of biphosphonates for areas of high bone turnover; Studies of several biphosphonates; Superiority of pamidronate in both rate and duration of response; Toxic effects of...

  • Compliance with drug therapy for postmenopausal osteoporosis. Weycker, D.; Macarios, D.; Edelsberg, J.; Oster, G. // Osteoporosis International;Nov2006, Vol. 17 Issue 11, p1645 

    Patient compliance with pharmacotherapy for osteoporosis is typically poor in clinical practice; less frequent dosing with bisphosphonates may improve compliance. Using data from 49 US health plans, we identified all women aged ≥45 years with osteoporosis who initiated therapy with a...

  • Treatment for osteoporosis.  // Geriatrics;Dec95, Vol. 50 Issue 12, p16 

    Reports on the approval by the US Food and Drug Administration of alendronate sodium, an amino-bisphosphonate, for the treatment of osteoporosis in women.

  • Alendronate: An Update of its Use in Osteoporosis. Sharpe, M.; Noble, S.; Spencer, C.M. // Drugs;May2001, Vol. 61 Issue 7, p999 

    Alendronate (alendronic acid) is a nitrogen-containing bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Oral alendronate 5 or 10 mg/day produces sustained increases in bone mineral density (BMD) in postmenopausal women with or without osteoporosis, in men...

  • Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Bobba, Raja S.; Beattie, Karen; Parkinson, Bill; Kumbhare, Dinesh; Adachi, Jonathan D. // Drug Safety;2006, Vol. 29 Issue 12, p1133 

    Bisphosphonates are the primary pharmacological agents used for the management of osteoporosis and hypercalcaemia of malignant bone disease. The efficacy of these agents in these two conditions has been demonstrated in many well designed trials published over the past 2 decades. The variety of...

  • Rheumatology: 15. Osteoporosis. Wade, John P. // CMAJ: Canadian Medical Association Journal;7/10/2001, Vol. 165 Issue 1, p45 

    Presents a case of osteoporosis, which may increase in risk in Canada and the United States as the population ages. Diagnosing osteoporosis, and estimating fracture risk using bone mineral density studies; Treatment; Lifestyle factors which could influence osteoporosis, including smoking, which...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics